Navigation Links
Epitope in Medical Technology

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... that targets a membrane-proximal (close to the cell surface), small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B cells.(4) This epitope is different from the binding sites targeted by other CD20 antibodies ...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... research and development activities with its L.E.A.P.S.(TM) (Ligand epitope Antigen Presentation System) technology. L.E.A.P.S.(TM) is a novel T-cell ... peptides. The L.E.A.P.S.(TM) constructs containing the antigenic disease epitope linked to a T-cell binding ligand (TCBL) can be manufactured by peptide ...

Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study

... fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 molecule on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 molecule. Ofatumumab is being developed to treat CLL, ...

Genmab Reaches Milestone in Ofatumumab Collaboration

... next generation monoclonal antibody that targets a distinct small loop epitope on the CD20 receptor on the surface of B-cells. This epitope is different from the other anti-CD20 antibodies currently available or in ...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

... function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T cells and by doing so, may modulate the immunologic response that is a key component of the disease. ...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

... data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A.P.S.(TM) (Ligand epitope Antigen Presentation System) vaccine technology with specificity for particular Mycobacterium tuberculosis (TB) antigens can elicit immune ...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

... About Ofatumumab Ofatumumab is an investigational monoclonal antibody that targets a membrane-proximal (close to the cell surface), small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B-cells. Ofatumumab also binds to the large loop of the CD20 molecule. ...

Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy

... is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's products offer potential major clinical benefits compared with existing therapies, and ...

Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients

... is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's anti-allergy products offer potential major clinical benefits compared with existing therapies, ...

Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment

... nearly 10% of Europeans suffering from the condition. Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. In addition to ToleroMune's potential therapeutic benefits, its state-of-the-art manufacturing processes fit ...

Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology

... Lansdowne Partners, Goldman Sachs and Invesco Perpetual. Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach ...

Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology

... Lansdowne Partners, Goldman Sachs and Invesco Perpetual. Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach ...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

... and their physicians." Ofatumumab is an investigational new generation fully human monoclonal antibody that uniquely targets the small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular ...

IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients

... from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using ...

IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients

... from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using ...

MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus

... function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T cells and by doing so, may modulate the immunologic response that causes disease. About Type 1 ...

ARIUS to Present at American Association for Cancer Research Annual Meeting

... of our FunctionFIRST(TM) platform to generate novel antibodies with promising anti-cancer properties." Novel antibody ARH460-16-2 recognizes an epitope of CD44 that is highly expressed in liver cancers. Abstract 662, Section 27, Board 15, Sunday, Apr 15, 8AM - 12PM ARH460-16-2, a functional ...

ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting

... IMC-EB10, NC7, and D4-3 (Anti-FLT3 MAb) (#4110 Williams et al. Elucidation of the antagonistic mechanisms of various anti-FLT3 antibodies via binding epitope dissection.) -- IMC-D11 (anti-FGFR3 MAb) (#2080 DiRenzo et al. Neutralizing antibody against FGFR3 shows anti-tumor effects in multiple ...

IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting

... the cancer as diseased tissue, is broken by using these analog epitopes which enhance the potency of the T cell response. PADRE(R), a universal HTL epitope we have licensed from Pharmexa, is also included in the vaccine as an immunostimulant. The phase II EP-2101 study has been ongoing since late 2004. ...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

... indicate therapy of tumors can be achieved with 500 microCi of Y-90 or less. About hPAM4 hPAM4 is a humanized monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancer, but not pancreatitis, normal pancreas or most other normal tissues. Preclinical studies with ...

New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus

... need to be updated. As such they do not provide protection against emerging flu strains, such as seasonal or avian flu. Using a novel proprietary epitope prediction algorithm, PepTcell has successfully identified immunogenic regions of flu virus that have not changed over 60 years, in both human and ...

New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus

... need to be updated. As such they do not provide protection against emerging flu strains, such as seasonal or avian flu. Using a novel proprietary epitope prediction algorithm, PepTcell has successfully identified immunogenic regions of flu virus that have not changed over 60 years, in both human and ...

Pharmexa A/S (DK) - Pharmexa presents data from influenza program

... infection. The vaccine is designed to induce T-cell responses to highly-conserved influenza epitopes that were identified using the proprietary epitope Identification System (EIS®). Pharmexa-Epimmune's approach is unique to the field where most vaccines are designed with the explicit goal of ...
Other Contents
(Date:9/30/2014)... HEIGHTS, Ill. (September 30, 2014) People who suffer ... can do to control their asthma besides properly taking ... a new article in the Annals of Allergy, ... American College of Allergy, Asthma and Immunology (ACAAI), asthma ... examining their lifestyle. The woman described in the Annals ...
(Date:9/29/2014)... Monday, September 29: Between 1970 and 2010 populations ... the globe dropped 52 percent, says the 2014 ... Fund (WWF). This biodiversity loss occurs disproportionately in ... of high-income countries. , In addition to the ... point to other warning signs about the overall ...
(Date:9/29/2014)... In order to support the world,s needs to ... and more, new and more efficient catalytic materials ... researchers, including several from Wayne State University, is ... new grant from the National Science Foundation. , ... of Multicomponent Materials for Electrocatalytic Cascade Reactions," was ...
Breaking Biology News(10 mins):Asthma symptoms kicking up? Check your exposure to air pollution 2Half of global wildlife lost, says new WWF report 2Wayne State research aims to develop new, more efficient catalytic materials 2
(Date:9/30/2014)... 2014 Research by UC Irvine immunologists reveals new ... on a vital process that determines how the body,s ... version of Nature Immunology , neurology professor Dr. ... for Immunology colleagues describe a critical mechanism underlying how ... bloodstream. , A T cell is a type of ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 EverStryke ... a free introduction to SurvivalLife.com along with a free book ... the attention of Shane Michaels, prompting an investigative review. ... well-known people in the survival and preparation niche, and this ... of the great classes and survival products that Joe offers ...
(Date:9/30/2014)... 30, 2014 VisitandCare.com reports ... has gone up more than 79 percent in 2014, ... company also reported total revenue tripled for its entirety ... company’s professional strategy has allowed them to partner with ... for patient comfort and privacy — with state-of-the-art surgical ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
(Date:9/30/2014)... 30, 2014 Bifidobacteria, the primary bacteria ... poor diet, and stress, so a high Bifido probiotic ... of Ultimate Flora™ Men’s Complete contains 90 ... 7 Bifidobacteria strains to support a healthy large intestine ... up, and 32 billion cultures from 7 Lactobacillus strains ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Regenerative Medicine Solutions Expanding 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
Other TagsOther Tags